Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates

Clinical and Experimental Immunology

Volumn 119, Issue 3, 2000, Pages 559-565

  Sivasai, K S R ^a   Mohanakumar, T ^a   Phelan, D ^a   Martin, S ^a   Anstey, M E ^a   Brennan, D C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytogam sensitized patients; IVIG; T cell response

Indexed keywords

ALLOANTIGEN; ANTIIDIOTYPIC ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; HLA ANTIBODY;

ADULT; ALLOIMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HLA SYSTEM; HUMAN; KIDNEY TRANSPLANTATION; LYMPHOCYTOTOXICITY; MALE; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL;

EID: 0034059668     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01138.x     Document Type: Article

References (63)

1. 1 Reynaert M, Chiolero R, Bickle M et al. Prophylactic intravenous administration of standard immune globulin as compared with corelipopolysacchride immune globulin in patients at high risk of post-surgical infection. N Engl J Med 1992; 327:234-40.
2. 2 Reynaert M, Chiolero R, Bickle M et al. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325:73-80.
3. 3 Filipovich AH, Peltier MH, Bechtel MK, Dirksen CL, Strauss SA, Englund JA. Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients. Blood 1992; 80:2656-60.
4. 4 Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3.
5. 5 Sigman K, Ghibu F, Sommerville W et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998; 102:421-7.
6. 6 Tekgul H, Kutukculer N, Caglayan S, Tutuncuoglu S. Pro-inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in Guillain-Barre syndrome. Turk J Pediatr 1998; 40:357-63.
7. 7 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92:2707-11.
8. 8 Harris EN, Pierangeli SS. Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol Suppl 1998; 107:97-102.
9. 9 Shambal S, Lindner A, Zierz S. Successful treatment of orbital myositis with intravenous immunoglobulins. Muscle Nerve 1998; 21:1359-60.
10. 10 Furuya Y, Takahashi T, Hamamoto H, Nishimura M, Kawakami Y. High-dose immunoglobulin therapy for a patient with dermatomyositis. Intern Med 1998; 37:642-5.
11. 11 Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102:910-8.
12. 12 Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998; 81:153-8.
13. 13 Lawn N, Wijdicks EF, Burritt MF. Intravenous immune globulin and pseudohyponatremia. N Engl J Med 1998; 339:632.
14. 14 Pascual J, Cid C, Berciano J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjogren's syndrome. Neurology 1998; 51:650-1.
15. 15 Bequet D, Deviere F, Renard JL, Felten D. Isaacs syndrome: longterm improvement with intravenous polyvalent immunoglobulins. Rev Neurol (Paris) 1997; 153:602-4.
16. 16 Colonna L, Cianchini G, Frezzolini A, DePita O, DiLella G, Puddu P. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy? Br J Dermatol 1998; 138:1102-3.
17. 17 Moore JP. Clinical trials of HIVIG. J Infect Dis 1998; 178:597-9.
18. 18 Foot AB, Pamphilon D, Caul EO et al. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts. Br J Haematol 1998; 102:671-7.
19. 19 George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103:106-13.
20. 20 Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against auto-antibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110: 135-49.
21. 21 Ronda N, Kaveri SV, Kazatchkine MD. Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network. Clin Exp Immunol 1993; 93:14.
22. 22 Jordan SC. Intravenous gamma globulin therpay in SLE and immune complex diseases. Clin Immunol Immunopathol 1989; 53:S164.
23. 23 Forsgren S, Andersson A, Hillorn V, Soderstrom A, Holmberg D. Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Scand J Immunol 1991; 34:445.
24. 24 Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 1994; 97:31.
25. 25 Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. New Engl J Med 1990; 323:705-12.
26. 26 Yadin O, Sekiya NM, Ettenger RB. Intravenous immunoglobulin (IVIg) reduces antibody responses in highly sensitized dialysis patients. J Am Soc Nephrol 1992; 3:887.
27. 27 Tyan D, Li V, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly-sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553.
28. 28 Glotz D, Haymann J, Naiudet P, Lang P, Druet P, Bairety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995; 27:1038.
29. 29 Bunchman TE, Parekh RS, Kershaw DB et al. Beneficial effect of sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clin Transplant 1997; 11:604-7.
30. 30 Blazczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparation. Lancet 1993; 341:789-90.
31. 31 Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342:678.
32. 32 Kaveri S, Vassilev T, Hurez V et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97:865-9.
33. 33 Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91:602-7.
34. 34 Snydman DR, Werner BG, Leinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomagalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317:1049-54.
35. 35 Snydman DR. Prevention of cytomegalovirus disease with intravenous immune globulin. Transplant Proc 1991; 23:66-7.
36. 36 Sharma LC, Lazarovits AI. Cytomegalovirus hyperimmune globulin improves longterm renal allograft survival. Nephrology 1997; 3:S195 (abstract).
37. 37 Basadonna G, Feria A, Perez R, Klein M, Sturges M, Colquhoun S. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation. Transplant Proc 1994; 26:52.
38. 38 Mathew JM, Marsh JW, Susskind B, Mohanakumar T. Analysis of T cell responses in liver allograft recipients: Evidence for deletion of donor specific cytotoxic T cells in the peripheral circulation. J Clin Invest 1992; 32:143.
39. 39 Poindexter NJ, Naziruddin B, McCourt DW, Mohanakumar T. Isolation of a kidney-specific peptide recognized by alloreactive HLA-A3-restricted human CTL. J Immunol 1995; 154:3880-7.
40. 40 Ozturk G, Terasaki PI. Cytotoxic antibodies against surface immunoglobulins. Transplantation 1980; 29:140.
41. 41 Reed E, Hardy M, Lattes C et al. Effectiveness of anti-idiotypic antibodies to HLA on graft survival in renal allograft recipients. N Engl J Med 1987; 316:1450-5.
42. 42 Mathew JM, Shenoy SPD, Lowell J, Howard T, Mohanakumar T. Biochemical and immunological evaluation of donor-specific soluble HLA in the circulation of liver transplant recipients. Transplantation 1996; 62:217-23.
43. 43 Gjorstrup. Anti-HLA antibody removal in hyperimmunized ESRF patients to allow transplantation. Transplant Proc 1991; 23:392.
44. 44 Johnson E, Fischel R, Boyle E, Matas A, Bolman RM III. Plasma exchange, splenectomy, and cyclophosphamide for natural antibody removal: kinetics and xenograft survival. Transplant Proc 1992; 24:701.
45. 45 Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107.
46. 46 Yadin O, Dewing P, Ma JP, Ettenger RB. Cytomegalovirus hyper-immune gammaglobulin downregulates in vitro T cell responses. Transplant Proc 1996; 28:7-8.
47. 47 Toyoda M, Zhang X, Petrosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma globulin. Transplant Immunol 1994; 2:337.
48. 48 Wolf-Levin R, Azuma T, Aoki K, Yagami Y, Okada H. Specific IgG autoantibodies are potent inhibitors of autoreactive T cell response to phytohemagglutinin-activated T cells. J Immunol 1993; 151:5864.
49. 49 Amran A, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180.
50. 50 VanSchaik I, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12:325.
51. 51 Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21.
52. 52 Toyoda M, Zhang X, Petrosian A, Galera O, Wang S-J, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by IVIG. J Clin Immunol 1994; 14:178.
53. 53 Dinarello C. Is there a role for Interleukin-1 blockade in IVIG therapy? Immunol Rev 1994; 139:173.
54. 54 Arend WP, Leung DYM. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1996; 139:71-8.
55. 55 Prasad NK, Papoff G, Zeuner A et al. Therapeutic preparations of normal polyspecific IgG (i.v. Ig) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of i.v. Ig involving the Fas apoptotic pathway. J Immunol 1998; 161:3781-90.
56. 56 Jordan SC, Tyan D. Intravenous gamma globulin (IVIG) inhibits lymphocytotoxic antibody in vitro. J Am Soc Nephrol 1991; 2:803.
57. 57 Glotz D, Haymann J-P, Francois A, Sansonnetti N, Druet P. Suppression of HLA-specific alloantibodies by high-dose IVIG. Transplantation 1993; 56:335.
58. 58 McIntyre JA, Higgins N, Britton R et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996; 62:691-3.
59. 59 Majluf-Cruz A, Luna-Castanos G, Huitron S, Nieto-Cisneros L. Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS. Am J Hematol 1998; 2:127-32.
60. 60 Mollnes TE, Hogasen K, DeCarolis C et al. High dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48:312-7.
61. 61 Casadei D, Rial M, Argento J, Goldberg J, Raimondi E. Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections. Transplant Proc 1998; 30:2164.
62. 62 Phelan DL, Canter C, Murphy P, Mohanakumar T. Successful heart transplantation in the presence of donor specific antibody by the use of intravenous gamma globulin and plasmapheresis. Hum Immunol 1997; 55:14.
63. 63 Nachbaur D, Herold M, Gachter A, Niederwieser D. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin press (pentaglobin). Immunology 1998; 94:279-83.